Kabuki syndrome (KS) is a rare congenital disorder commonly complicated by humoral immunodeficiency. Patients with KS present with mutation in the histone-lysine N-methyltransferase 2D (KMT2D) gene. Although various KMT2D mutations are often identified in lymphoma and leukemia, those encountered in aplastic anemia (AA) are limited. Herein, we present the case of a 45-year-old Japanese man who developed severe pancytopenia and hypogammaglobulinemia. He did not present with any evident malformations, intellectual disability, or detectable levels of autoantibodies. However, B-cell development was impaired. Therefore, a diagnosis of very severe AA due to a hypoplastic marrow, which did not respond to granulocyte colony-stimulating factor, was made. The patient received umbilical cord blood transplantation but died from a Pseudomonas infection before neutrophil engraftment. Trio whole-exome sequencing revealed a novel missense heterozygous mutation c.15959G >A (p.R5320H) in exon 50 of the KMT2D gene. Moreover, Sanger sequencing of peripheral blood and bone marrow mononuclear cells and a skin biopsy specimen obtained from this patient identified this heterozygous mutation, suggesting that de novo mutation associated with KS occurred in the early embryonic development. Our case showed a novel association between KS mutation and adult-onset AA.

1.
Froimchuk
E
,
Jang
Y
,
Ge
K
.
Histone H3 lysine 4 methyltransferase KMT2D
.
Gene
.
2017 Sep 5
;
627
:
337
42
. .
2.
Fagan
RJ
,
Dingwall
AK
.
COMPASS ascending: emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer
.
Cancer Lett
.
2019 Aug 28
;
458
:
56
65
. .
3.
Ortega-Molina
A
,
Boss
IW
,
Canela
A
,
Pan
H
,
Jiang
Y
,
Zhao
C
,
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development
.
Nat Med
.
2015 Oct
;
21
(
10
):
1199
208
. .
4.
Zhang
J
,
Dominguez-Sola
D
,
Hussein
S
,
Lee
JE
,
Holmes
AB
,
Bansal
M
,
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis
.
Nat Med
.
2015 Oct
;
21
(
10
):
1190
8
. .
5.
Rushton
CK
,
Arthur
SE
,
Alcaide
M
,
Cheung
M
,
Jiang
A
,
Coyle
KM
,
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma
.
Blood Adv
.
2020 Jul 14
;
4
(
13
):
2886
98
. .
6.
Niikawa
N
,
Kuroki
Y
,
Kajii
T
,
Matsuura
N
,
Ishikiriyama
S
,
Tonoki
H
,
Kabuki make-up (Niikawa-Kuroki) syndrome: a study of 62 patients
.
Am J Med Genet
.
1988 Nov
;
31
(
3
):
565
89
. .
7.
Ming
JE
,
Russell
KL
,
McDonald-McGinn
DM
,
Zackai
EH
.
Autoimmune disorders in Kabuki syndrome
.
Am J Med Genet A
.
2005 Jan 30
;
132A
(
3
):
260
2
. .
8.
Stagi
S
,
Gulino
AV
,
Lapi
E
,
Rigante
D
.
Epigenetic control of the immune system: a lesson from Kabuki syndrome
.
Immunol Res
.
2016 Apr
;
64
(
2
):
345
59
. .
9.
Lindsley
AW
,
Saal
HM
,
Burrow
TA
,
Hopkin
RJ
,
Shchelochkov
O
,
Khandelwal
P
,
Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome
.
J Allergy Clin Immunol
.
2016 Jan
;
137
(
1
):
179
87.e10
. .
10.
Bögershausen
N
,
Wollnik
B
.
Unmasking Kabuki syndrome
.
Clin Genet
.
2013 Mar
;
83
(
3
):
201
11
. .
11.
Yamamoto
H
,
Kato
D
,
Uchida
N
,
Ishiwata
K
,
Araoka
H
,
Takagi
S
,
Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia
.
Blood
.
2011 Mar 17
;
117
(
11
):
3240
2
. .
12.
Ochi
T
,
Onishi
Y
,
Nasu
K
,
Onodera
K
,
Kobayashi
M
,
Ichikawa
S
,
Umbilical cord blood transplantation using reduced-intensity conditioning without antithymocyte globulin in adult patients with severe aplastic anemia
.
Biol Blood Marrow Transplant
.
2019 Feb
;
25
(
2
):
e55
9
. .
13.
Tamura
S
,
Higuchi
K
,
Tamaki
M
,
Inoue
C
,
Awazawa
R
,
Mitsuki
N
,
Novel compound heterozygous DNA ligase IV mutations in an adolescent with a slowly-progressing radiosensitive-severe combined immunodeficiency
.
Clin Immunol
.
2015 Oct
;
160
(
2
):
255
60
. .
14.
Kallen
ME
,
Dulau-Florea
A
,
Wang
W
,
Calvo
KR
.
Acquired and germline predisposition to bone marrow failure: diagnostic features and clinical implications
.
Semin Hematol
.
2019 Jan
;
56
(
1
):
69
82
. .
15.
Zhang
J
,
Dominguez-Sola
D
,
Hussein
S
,
Lee
JE
,
Holmes
AB
,
Bansal
M
,
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis
.
Nat Med
.
2015 Oct
;
21
(
10
):
1190
8
. .
16.
Luzzatto
L
,
Risitano
AM
.
Advances in understanding the pathogenesis of acquired aplastic anaemia
.
Br J Haematol
.
2018 Sep
;
182
(
6
):
758
76
. .
17.
Risitano
AM
.
(Auto-)immune signature in aplastic anemia
.
Haematologica
.
2018 May
;
103
(
5
):
747
9
. .
18.
Lu
S
,
Yadav
AK
,
Qiao
X
.
Identification of potential miRNA-mRNA interaction network in bone marrow T cells of acquired aplastic anemia
.
Hematology
.
2020 Dec
;
25
(
1
):
168
75
. .
19.
Yoshizato
T
,
Dumitriu
B
,
Hosokawa
K
,
Makishima
H
,
Yoshida
K
,
Townsley
D
,
Somatic mutations and clonal hematopoiesis in aplastic anemia
.
N Engl J Med
.
2015 Jul 2
;
373
(
1
):
35
47
. .
20.
Larsson
CA
,
Cote
G
,
Quintás-Cardama
A
.
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome
.
Mol Cancer Res
.
2013 Aug
;
11
(
8
):
815
27
. .
21.
Chen
Y
,
Anastassiadis
K
,
Kranz
A
,
Stewart
AF
,
Arndt
K
,
Waskow
C
,
MLL2, not MLL1, plays a major role in sustaining MLL-rearranged acute myeloid leukemia
.
Cancer Cell
.
2017 Jun 12
;
31
(
6
):
755
70.e6
. .
22.
Killick
SB
,
Bown
N
,
Cavenagh
J
,
Dokal
I
,
Foukaneli
T
,
Hill
A
,
Guidelines for the diagnosis and management of adult aplastic anaemia
.
Br J Haematol
.
2016 Jan
;
172
(
2
):
187
207
. .
23.
Scheinberg
P
.
Novel therapeutic choices in immune aplastic anemia
.
F1000Res
.
2020 Sep 10
;
9
:
1118
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.